Nature Biotechnology - Phosphoinositide profiling in complex lipid mixtures using electrospray ionization mass spectrometry Skip to main content Thank you for visiting nature.com.

2021年1月30日 讯 /生物谷BIOON/ --近日，一项刊登在国际杂志Science上题为“Glycolysis fuels phosphoinositide 3-kinase signaling to bolster T cell immunity”的研究报告中 ...

生物通报道：p85是著名因子磷脂酰肌醇3激酶（Phosphoinositide 3 kinase，PI3K）的一个85 kDa大小的调节亚基，近年来科学家们发现了越来越多的这种亚基编码基因：PIK3R1的突变，而这种基因又与结肠癌等多种癌症发病存在相关性，因此其研究备受关注。 近期来自德州大学西南医学中心等处的研究人员发表 ...

Variants of these genes lead to hyperactivity of the phosphoinositide 3-kinase delta (PI3Kδ) pathway resulting in immunodeficiency and dysregulation. Leniolisib is an oral, selective PI3Kδ ...

Background: Glioblastoma is one of medicine's most difficult-to-treat cancers due to its inevitable resistance to chemotherapies, such as temozolomide (TMZ). Tumor resistance to TMZ often comes from ...

Purpose Buparlisib, an oral reversible inhibitor of all class I phosphoinositide-3-kinases, has shown antitumoral activity against estrogen receptor (ER)-positive breast cancer cell lines and ...

PRMC-MS enables the comprehensive analysis of phosphoinositide acyl variants in various types of biological samples, including surgical specimens, which can be used to throw a light on previously ...

Leniolisib (Joenja) is available on the NHS as a possible treatment for activated phosphoinositide 3-kinase delta syndrome in people 12 years and over. Is this treatment right for me? Your healthcare ...

Leniolisib (Joenja, Pharming) is indicated for 'the treatment of activated phosphoinositide 3‑kinase delta (PI3Kδ) syndrome (APDS) in adult and paediatric patients 12 years of age and older'. The ...

Variants of these genes lead to hyperactivity of the phosphoinositide 3-kinase delta (PI3Kδ) pathway resulting in immunodeficiency and dysregulation. Leniolisib is an oral, selective PI3Kδ ...

In a new study published in the journal Nature (“A Phosphoinositide Signaling Pathway Mediates Rapid Lysosomal Repair”), scientists at the University of Pittsburgh, have identified a new ...